Novo Nordisk today announced plans to invest more than DKK 42 bn starting in 2023 to expand existing manufacturing facilities in Kalundborg, Denmark. NNE has been assigned the engineering task as Novo Nordisk’s partner from design to construction.
NNE has delivered the conceptual and basic design for the new facility at the Kalundborg manufacturing site and can now start the construction.
A major milestone in NNE history
For CEO of NNE, Jesper Kløve, this is a great achievement for NNE:
“I want to thank Novo Nordisk for assigning NNE this major project. Being entrusted with something so important comes with responsibility, and we will do our utmost to deliver an excellent result using our capabilities and expertise within the pharma engineering field,” he says and concludes:
“Our dedicated team of professionals have already started the initial work to ensure the new facility will live up to the highest standards. We are designing a facility at the forefront of technology, making it future-proof in terms of pharmaceutical production and sustainability. NNE has a proven track record of completing complex engineering projects on time and within budget, and we are committed to maintaining this high standard on this new project. We are looking forward to collaborating with Novo Nordisk to bring their vision to life.”
For more information
For general questions about the project, please refer to the press release sent out by Novo Nordisk.